Claims for Patent: 10,076,505

Summary for Patent: 10,076,505

Title:	Inhalation formulations of Treprostinil
Abstract:	The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
Inventor(s):	Wade; Michael (Chapel Hill, NC)
Assignee:	United Therapeutics Corporation (Silver Spring, MD)
Application Number:	15/657,933
Patent Claims:	1. A parenteral formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer. 2. The parenteral formulation of claim 1, which is sterile and isotonic with blood. 3. The parenteral formulation of claim 1, which is an injectable formulation. 4. The parenteral formulation of claim 1, which is an intravenously administered formulation. 5. The parenteral formulation of claim 4, wherein the formulation is sterile and isotonic with blood. 6. The parenteral formulation of claim 4, wherein the formulation is configured for administration at a rate of 0.625 to 50 ng/kg/min. 7. The parenteral formulation of claim 4, wherein the formulation is configured for administration at a rate of 10 to 15 ng/kg/min.